DrugPatentWatch Database Preview

Details for Patent: 9,227,946

« Back to Dashboard

Which drugs does patent 9,227,946 protect, and when does it expire?

Patent 9,227,946 protects TRINTELLIX and is included in one NDA.

This patent has seventy-four patent family members in thirty-two countries.

Summary for Patent: 9,227,946

Title:	1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
Abstract:	1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT.sub.3 and 5-HT.sub.1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
Inventor(s):	Faldt; Andre (Ishoj, DK), Holm; Rene (Jyllinge, DK), de Diego; Heidi Lopez (Naerum, DK)
Assignee:	H. Lundbeck A/S (Copenhagen-Valby, DK)
Application Number:	14/242,337
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,227,946

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-001	Sep 30, 2013		RX	Yes	No						METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-002	Sep 30, 2013		RX	Yes	No						METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-003	Sep 30, 2013		DISCN	Yes	No						METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-004	Sep 30, 2013		RX	Yes	Yes						METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER

Foreign Priority and PCT Information for Patent: 9,227,946

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Denmark	200600824	Jun 16, 2006
Denmark	200601223	Sep 22, 2006
Denmark	200601384	Oct 25, 2006
Denmark	200700427	Mar 20, 2007

Non-Orange Book US Patents Family Members for Patent 9,227,946

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
9,861,630	1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment
9,125,909	1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment
8,969,355	1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
9,095,588	Process for preparing 1-[2-(2,4-dimethylphenysulfanyl)-pheny]piperazine or pharmaceutically acceptable salt thereof

International Family Members for US Patent 9,227,946

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	061481
Argentina	065797
Austria	495745
Austria	540941